2022
Patterns and trends in the cause of death for patients with endometrial cancer
Ran X, Yang H, Yu X, Lu L, Wang Y, Ji J, Xu M, Wei W, Li B, Zeng H. Patterns and trends in the cause of death for patients with endometrial cancer. JNCI Cancer Spectrum 2022, 7: pkac082. PMID: 36420983, PMCID: PMC9808774, DOI: 10.1093/jncics/pkac082.Peer-Reviewed Original ResearchConceptsEndometrial cancer patientsEndometrial cancerCause of deathCause deathCumulative incidenceBlack-White disparitiesHistological subtypesCancer patientsPopulation-based cohort studyProportional subdistribution hazardsRacial disparitiesPrimary endometrial cancerCause-specific hazards modelEnd Results ProgramRisk of deathCohort studyWhite patientsBlack patientsSurgery utilizationResults ProgramRelative riskHazards modelPatientsCancerDeath
2017
Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival
Yang JC, Risch E, Zhang M, Huang C, Huang H, Lu L. Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival. Future Oncology 2017, 13: 1981-1990. PMID: 28829218, DOI: 10.2217/fon-2017-0084.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAgedAged, 80 and overBiomarkers, TumorCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleFollow-Up StudiesHumansInsulin-Like Growth Factor IIMethyltransferasesMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsPrognosisSurvival RateConceptsOvarian cancer survivalIGF-IICancer survivalOvarian cancerDisease progression-free survivalMultivariate Cox regression modelProgression-free survivalRisk of deathCox regression modelIGF-II expressionClinical followSurvival analysisClinical implicationsIGFNormal tissuesHeterogeneous outcomesSurvivalCancerMolecular signaturesAssociationRegression modelsRNA sequencingSupNSUN2RelapseIFNγ enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells
Shao S, Risch E, Burner D, Lu L, Minev B, Ma W. IFNγ enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells. International Immunopharmacology 2017, 47: 159-165. PMID: 28410529, DOI: 10.1016/j.intimp.2017.04.003.Peer-Reviewed Original ResearchConceptsCytotoxic T lymphocytesPositive glioma cellsT cell activation scoreMHC class IGlioma cellsClass IT lymphocytesTumor antigen-specific cytotoxic T lymphocytesAntigen-specific cytotoxic T lymphocytesIFNγ treatmentActivity of CTLHuman dendritic cellsRisk of deathHuman leukocyte antigenActivation scoresLow-grade gliomasMHC class I moleculesClass I moleculesHuman glioma cellsCytotoxic efficiencyDendritic cellsTumor immunityLeukocyte antigenCancer immunotherapyGlioma patients
2015
MicroRNA let‐7a modifies the effect of self‐renewal gene HIWI on patient survival of epithelial ovarian cancer
Lu L, Katsaros D, Risch HA, Canuto EM, Biglia N, Yu H. MicroRNA let‐7a modifies the effect of self‐renewal gene HIWI on patient survival of epithelial ovarian cancer. Molecular Carcinogenesis 2015, 55: 357-365. PMID: 25630839, DOI: 10.1002/mc.22285.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerKaplan-Meier survival curvesOverall survivalHIWI expressionLet-7a expressionPatient survivalLet-7aClinical relevanceMultivariate Cox proportional hazards regression analysisCox proportional hazards regression analysisCox proportional hazards regression modelSurvival curvesProportional hazards regression analysisProportional hazards regression modelsLow let-7aHazards regression analysisRisk of deathPoor overall survivalHazards regression modelsMiRNA let-7aPrimary EOC tissuesQuantitative reverse transcription PCRU-shape associationEOC prognosisPrognostic significance
2011
Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome
Lu L, Zhang C, Zhu G, Irwin M, Risch H, Menato G, Mitidieri M, Katsaros D, Yu H. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Research 2011, 13: r56. PMID: 21645396, PMCID: PMC3218945, DOI: 10.1186/bcr2893.Peer-Reviewed Original ResearchConceptsEndocrine therapyDisease outcomeAdjuvant treatmentTelomerase expressionBetter survival outcomesDisease-free survivalHormone receptor statusBreast cancer patientsRisk of deathTelomere lengthHigh telomeraseCause-specific mortalityBreast cancer prognosisBreast cancer cellsCancer cell resistanceHigh telomerase expressionOverall survivalPatient ageDisease recurrenceReceptor statusHistological typeAggressive diseaseSurvival outcomesDisease stageCancer patients